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ABSTRACT 
 
An implantable rapid drug delivery device based on micro-electro-mechanical systems 
(MEMS) technology was designed, fabricated and validated for the in vivo rapid delivery 
of vasopressin in a rabbit model.  In vitro characterization of device performance found 
the device capable of reliably and reproducibly delivering 85% of its loaded drug solution. 
 
A comparison of intraperitoneal and subcutaneous injections of vasopressin in rabbits 
was performed to determine the implantation location for the device.  Both routes of 
delivery were found to be viable implantation locations, and the less invasive 
subcutaneous site was chosen. 
 
Vasopressin was released from the subcutaneously implanted device in anesthetized 
rabbits and found to exert a measurable effect on blood pressure.  The bioavailability of 
vasopressin delivered from the device was found to be 6.2% after one hour. 
 
Proof-of-concept experiments were also conducted to address long-term stability of drugs 
in the implanted device and wireless activation of the device.  These experiments defined 
areas of future research for improvement of the device. 
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CHAPTER 1: INTRODUCTION 
 
1.1. Implantable Drug Delivery Devices 
Drug delivery is a broad term that refers to the method by which a drug is 
delivered to its site of action.  The most commonly known types of drug delivery are oral 
(e.g. pills, syrups), topical (e.g. creams), inhalation (e.g. aerosols) and transmucosal (e.g. 
sublingual, ocular, rectal) delivery.  They are widely used because of their non-
invasiveness.  Diseases or conditions which are increasingly difficult to treat require 
increasingly complex or potent medications, however.  The available means of delivery 
generally become more restricted, because these complex medications become 
susceptible to the first-pass effect, i.e., enzymatic degradation in the digestive tract or 
liver, or because of difficulties in reaching target areas through the circulatory system.  
Vaccines and antibodies, for example, must be injected due to a large first-pass effect if 
ingested.  Some medications must also be injected directly into their action site, because 
the systemic levels necessary to reach therapeutic levels in the target zone are toxic.  
Many cancer drugs belong in this category, such as carmustine and temozolomide.  These 
action sites are not always accessible because of their location, or because the length 
and/or frequency of access necessary for therapeutic treatment greatly affect the patient’s 
quality of life. 
The brain is a difficult target zone, for example.  Drug therapy targeted at the 
brain is difficult to achieve by systemic injection with many drugs.  The blood-brain 
barrier hampers drug absorption from blood vessels into the brain.  This barrier requires 
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toxic systemic drug levels to achieve therapeutic effects in the brain.  Direct access is 
impossible without major surgery, precluding any repeated treatments.  Another difficult 
location is the bladder.  Some diseases affecting the bladder, such as interstitial cystitis, 
can be alleviated by direct infusion of therapeutics into the bladder, achieved by 
introducing a catheter through the urethra [1].  This procedure is very uncomfortable for 
patients and is carried out several times a week, increasing risks for urinary tract infection, 
and affecting quality of life. 
Implanted drug delivery devices bring a solution to these problems, by delivering 
a drug regimen as effective as traditional therapy for extended periods of time in a 
particular location.  They remove the necessity for frequent access and always improve 
quality of life for the patient compared to traditional treatments.  Examples of these 
devices used commercially are the SynchroMed® system developed by Medtronic, Inc. 
for infusion of morphine directly into the cerebrospinal fluid; Gliadel®, a polymer wafer 
that slowly releases carmustine and is used in conjunction with resection of recurrent 
glioblastoma multiforme tumors in the brain; and drug-eluting stents that are widely used 
in angioplasty. 
 
1.2. MEMS Technology in Drug Delivery 
Micro-electro-mechanical systems (MEMS) technology is based on silicon 
microprocessor fabrication tools.  Its ability to produce micron-sized features in 
substrates such as silicon, glass and polymers has made it almost ubiquitous in the 
production of drug delivery devices, especially for implantable devices where size is a 
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concern.  Examples of drug delivery devices based on MEMS technology abound in the 
literature [2-4], but of particular interest in this work are devices fabricated in silicon. 
Multi-reservoir silicon devices have been shown to release efficacious amounts of 
carmustine to a tumor in rats [5].  In vivo release of leuprolide, a polypeptide used in 
prostate cancer and endometriosis treatments, has also been demonstrated [6].  These 
multi-reservoir devices allow control of therapeutic profiles and can be either 
preprogrammed or activated telemetrically.  Eventual integration of these devices with 
biosensors could result in fully automated therapeutic systems if medical personnel 
involvement is not necessary. 
 
1.3. Emergency Drug Delivery 
The majority of implantable drug delivery devices are used in the treatment of 
chronic illnesses, because they allow targeted therapeutic treatments for long periods of 
time while improving quality of life for patients.  Much time is allowed for preparation 
and implantation of devices, as therapeutic profile durations are on the order of days to 
weeks. 
Conditions with acute symptoms such as anaphylactic shock or cardiac arrest are 
unpredictable, although efforts have been undertaken to predict cardiac arrest [7, 8].  
Therapies have to be performed within minutes of the onset of symptoms to be effective 
and, in some cases, to avert permanent damage or death.  The only existing therapy with 
an implantable device is the implantable cardiac defibrillator, which can jolt a heart back 
to normal sinus rhythm when anomalies are detected.  Drug-based therapies consist of 
nitroglycerin pills to be placed sublingually for patients at risk for cardiac arrest, and 
  14 
Epipens® for patients susceptible to anaphylactic shock.  Epipens® are spring-loaded 
devices that immediately deliver an intramuscular dose of epinephrine when jammed 
against the thigh, allowing symptom relief before reaching a hospital.  These treatments 
require self-administration or help from another person, which is not always possible 
depending on the patient’s condition and location.  An implanted drug delivery device 
could ensure delivery no matter the circumstances when coupled with appropriate 
biosensors for a closed-loop system or when triggered by the patient for on-demand 
delivery.  Remote health monitoring systems in the future may even allow caregivers to 
remotely trigger drug delivery when an emergency occurs. 
An implantable rapid drug delivery device may also be useful in military conflicts.  
Combat conditions do not always allow emergency care to be administered to an injured 
soldier under heavy enemy fire.  Bleeding injuries can lead to massive blood loss if 
untreated, leading to hemorrhagic shock, a hypotensive state of deficient organ perfusion 
caused by the lack of blood.  Hemorrhagic shock, also known as hypovolemic shock, is 
the most common cause of preventable death in the Army [9].  It is treated in a civilian 
hospital setting by hemorrhage control, fluid replacement, and the injection of 
vasoconstrictors.  These measures can be delayed in a combat environment, leading to 
death.  Self-applied hemostatic dressings have been shown to help reduce bleeding on 
external wounds, but are not effective for internal bleeding or if too much blood has 
already been lost [9]. 
Voelckel et al have conducted a preclinical experiment in a pig hemorrhagic 
shock model where vasopressin injected intravenously was able to keep pigs alive for 30 
minutes without any other intervention, whereas epinephrine and placebo could not [10].  
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Vasopressin, also called antidiuretic hormone, is a peptide produced in the hypothalamus 
and secreted by the posterior pituitary gland of most mammals [11-13].  Its primary 
function is to regulate the body’s water retention by acting on the kidneys to reabsorb 
water and decrease urine output when high plasma osmolality is detected.  Loss of 
arterial blood pressure (due for example to blood loss) triggers release of a higher 
concentration of vasopressin that initiates arteriolar vasoconstriction, shunting blood from 
the limbs and mesenteric circulation towards the heart and brain.  Several case studies 
have illustrated the potential of exogenous vasopressin in delaying or reversing 
hemorrhagic shock in trauma victims [14-17].  A clinical trial has been started in January 
2009 in Europe, studying the potential benefits of vasopressin therapy in traumatic 
hemorrhagic shock [18].  The conclusions from this study may validate the use of 
vasopressin in standard treatments for hemorrhagic shock.  Wounded soldiers at risk for 
hemorrhagic shock may benefit from vasopressin only if it can be delivered in a timely 
manner.  An implanted drug delivery device that could be remotely activated by a medic 
would solve the problem of access to a wounded soldier when battle conditions do not 
allow the medic to be physically present. 
 
1.4. An Implantable Emergency Drug Delivery Device 
The previous discussion delineates the requirements for an implantable 
emergency drug delivery device, beside the usual requirement of biocompatibility.  These 
requirements are: 
- ability to rapidly release drug content; 
- long-term stability of drug in device; and 
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- wireless triggering for remote activation. 
This dissertation presents the proof-of-principle for an implantable MEMS drug 
delivery device operating on the principle of bubble nucleation to rapidly release its drug 
loading.  Vasopressin was chosen as a model drug for delivery not only because of its 
potential benefits in hemorrhagic shock, but also because of its expanding use in cardiac 
arrest [19, 20].  The device design, fabrication and in vitro characterization are discussed 
in Chapter 2 and have been published in an article co-authored with Dr. Noel Elman [21].  
The selection of a candidate location for implantation through pharmacokinetic 
measurements is described in Chapter 3, and in vivo testing of the device in the selected 
location is reported in Chapter 4.  Part of the work presented in both these chapters has 
been submitted for publication.  This work has focused primarily on the rapid delivery 
component of the device, but Chapter 5 offers some early experiments geared towards 
long-term stability of the drug and wireless activation. 
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CHAPTER 2: DEVICE FABRICATION AND 
CHARACTERIZATION 
 
2.1 Introduction 
Implantable drug delivery devices have demonstrated their great potential in a 
vast number of applications for which the controlled and accurate delivery of critically 
prescribed drug doses is required without direct medical intervention. A variety of 
implantable devices based on Micro-Electro-Mechanical-Systems (MEMS) technology 
has already been demonstrated for chronic illnesses.  These devices include micro-pumps 
[1] and multi-reservoir silicon chips [2, 3], for example.  Actively controlled devices 
provide advantages over passive release devices, which rely on the degradation chemistry 
of the device materials or on osmotic processes to release their load [4-6], as the drug 
delivery process can be controlled actively after implantation and even engaged 
telemetrically. 
MEMS technology has allowed the successful miniaturization of micro-pumps for 
drug delivery, enabling active delivery of fluids from single or multiple reservoirs. Low 
delivery rates, low reliability due to the dependence on mechanical moving parts in fluids, 
and high power consumption are among the prime limitations of an implantable drug 
delivery device that relies on micro-pumps.  Drug delivery devices characterized by 
multiple-reservoir architectures and based on electrical actuation mechanisms provide a 
more reliable platform. These devices typically rely on electro-thermal actuation to 
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rupture a reservoir sealing membrane as a result of an applied electrical potential, 
allowing the drugs inside of reservoirs to freely diffuse into the region of interest [7].   
A number of implantable drug delivery devices have been investigated for use in 
chronic and non-chronic diseases in ambulatory settings without medical intervention, 
such as cancer, diabetes, and osteoporosis [8].  These implantable devices provide a 
significant improvement in the bioavailability of drugs, but their use is mainly limited to 
treatment of chronic illnesses as they rely on diffusion and small delivery volumes, with 
complete release achieved in a few hours. Current implantable drug delivery devices 
based on MEMS technology are therefore not adequate as a solution for immediate 
treatment of illnesses in trauma care.  None of the currently available technologies for 
implantable drug delivery devices fulfill the requirements for rapid in vivo treatment of 
pathologies in emergency situations.  The challenge lies in the implementation of an 
active drug delivery device capable of storing large volumes, preferably without any 
moving parts to increase performance reliability, and mainly characterized by high 
delivery rates to achieve treatment in a few minutes as opposed to a few hours. The 
development of implantable devices for emergency treatments that require rapid and 
reliable drug delivery is thus the main motivation of this work. 
This chapter presents the first rapid drug delivery platform suitable for 
implementation as a smart micro-implant for high-risk patients. This novel device can be 
useful for a number of delivery modalities, including subcutaneous, intraperitoneal, 
intramuscular, and transdermal delivery.  Potential pathologies that the device can 
address with patients at high risk include cardiac arrest, angina, anaphylactic shock and 
epilepsy. The device’s goal is to provide a drug bolus in minutes or less upon triggering.  
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The work presented in this chapter has been published in Biomedical Microdevices [9] 
and is reproduced here with kind permission from Springer Science + Business Media, 
LLC.  © Springer Science + Business Media, LLC 2009. 
 
2.2. Device Architecture 
The modular device architecture allows separation of device opening and drug 
expulsion mechanisms, as well as customization of the drug load volume.  The 
architecture is shown schematically in Figure 2.1 and is comprised of three layers: a 
Pyrex single reservoir layer, where the drug solution is stored; a membrane layer that 
hermetically seals the drug reservoir, and from where the drug is ejected; and an 
actuation layer carrying the drug expulsion mechanism. 
The Pyrex macroreservoir is fabricated by drilling circular holes in a Pyrex 7740 
wafer.  Capacity is defined by the diameter of the drilled hole (3.6 mm) and thickness of 
the wafer (2.25 mm), and is currently 22.9 μL.  The modular design of the chip allows the 
capacity to be changed simply by changing the dimensions of the drilled hole, either by 
using a different thickness wafer or by changing the diameter of the hole. 
The membrane layer consists of free-standing silicon nitride membranes over 
square silicon through-wafer vias with dimensions 400 x 400 μm.  Silicon nitride is 
commonly used as a diffusion-stop layer in silicon technologies and prevents diffusion in 
or out of the reservoir, keeping the drug solution sealed until needed.  A gold line is 
patterned on top of the membrane to detect membrane rupture.  The gold circuit opens 
when the membrane, and consequently the gold line, is ruptured.  This allows membrane 
opening detection by monitoring the resistance across the line for an open-circuit. 
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The actuation layer contains patterned titanium resistors.  A current passed 
through the resistors produces heat by virtue of the Joule effect, generating thermal vapor 
bubbles in the solution.  These bubbles increase pressure inside the macroreservoir, until 
a silicon nitride membrane on the top chip ruptures.  The contents of the macroreservoir 
are then expelled out of the device due to the volume expansion that the vapor bubbles 
create, allowing the delivery of 20 μl of solution in 45 seconds of current application. 
All materials of construction of this device (silicon, silicon nitride, silicon dioxide, 
gold and titanium) have been shown to be biocompatible [10, 11].  The device 
operational design and principles are introduced, followed by experimental validation to 
address its performance characteristics. 
 
2.3. Device Design 
Bubble nucleation by heating a liquid is a well-known phenomenon, and can be 
initiated by electrically heating a resistive element to generate localized boiling. The 
sudden increase in pressure bursts a sealing membrane, thereby releasing the drugs at a 
high rate.  The design of the actuation layer is therefore critical for the performance of the 
device. The actuation layer consists of three resistive elements in parallel. The resistor 
area was designed to be compact in order to localize the heat transfer. The power density 
(amount of power per surface unit area of the resistor) was designed to reach 
approximately 25 W/mm2 in order to exceed the nucleate boiling threshold and enter the 
film boiling regime for water [12].  Film boiling is desired in order to insulate the bulk of 
the drug solution from the resistor surface, and prevent drug degradation due to 
overheating.  Titanium was chosen as material for the resistive element because it is 
  23 
biocompatible and characterized by a relatively high resistivity for metals.  This allows it 
to be patterned with the desired area while avoiding overly thin layers (< 200 Å) that 
might be needed with more conductive metals such as gold in order to achieve the 
appropriate resistances.  Three U-shaped resistors of 30 Ohms capable of delivering the 
required power density were designed to connect in parallel to achieve a 10-Ohm 
electrical resistance.  The thickness was optimized to achieve the desired resistor values 
in order to compensate for impurities in the Ti due to the deposition process. This step 
involved deposition of several thicknesses of Ti and subsequent measurements of sheet 
resistance using a four-point probe (Keithley SCS-4200, Keithley Instruments Inc., USA). 
The resultant thickness was 250 nm, providing a sheet resistance of 2.7 Ω/□. 
The membrane layer consists of a free-standing silicon nitride membrane that acts 
as a hermetic seal preventing both the drug inside of the reservoir to diffuse out, and any 
foreign substance to penetrate inside of the reservoir. Silicon nitride was chosen as the 
membrane material due to its high density and use as a diffusion-stop layer. Its 
mechanical properties allow limited elastic deformation while maintaining a hermetic 
seal. The membrane shatters into small fragments when the silicon nitride membrane is 
subjected to a critical pressure. The membrane dimensions were optimized to withstand 
external pressure and stresses involved in the handling and implantation of the device, but 
also to allow the membrane to burst when activation of the device increases pressure 
inside the device. A design based on a square membrane was chosen for its simplicity in 
implementation. A finite element analysis (FEA) tool (Cosmos, SolidWorks, Inc., USA) 
was used to simulate the failure points based on applied pressures for different membrane 
lateral dimensions, keeping the thickness to a constant 200 nm. The stresses were 
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simulated using the Von Mises method and the theoretical maximum tensile stress of 
amorphous silicon nitride (200 MPa), and meshed with 3x105 elements. The results of the 
simulation revealed that a 400-μm square membrane can withstand normal pressures of 
up to 5kPa, while maintaining an acceptable factor of safety. Calculations based on 
standard analytical solutions [13] also reveal that the chosen membrane dimensions are 
structurally robust for this application.  
 
2.4. Fabrication Process 
The device fabrication is comprised of three separate processes: the membrane 
layer, the reservoir layer, and the actuation layer. These processes are independent due to 
the modular architecture of the device, as was shown in Figure 2.1. The process for 
fabrication of these separate layers referred hereinafter is described in Figures 2.2 and 2.3.  
 
2.4.1. Membrane Layer 
The membrane layer comprised of an array of standing SiN membranes is 
combined with patterned gold fuses, which are designed to act as sensors.  A fuse is 
broken when a membrane is burst, resulting in an open circuit that can be detected by 
measuring the fuse resistance.  The membrane layer was fabricated using micro-
machining technology.  A 500 nm thermal silicon dioxide (SiO2) layer is grown on a 100 
mm, double polished, 300 μm thick, single-crystal-silicon (SCS) wafer, followed by 
deposition of a 200 nm layer of SiN by low-pressure vapor chemical deposition 
(LPCVD).  A 30 nm titanium adhesion layer and a 300 nm gold layer are then sputter-
deposited.  The first photolithographic step then defines the electrical fuses on top of the 
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membranes.  Gold and titanium are wet etched to form the fuses, shown in Figure 2.2A.  
The patterned wafer is then coated with a layer of photoresist for protection. The 
backside of the wafer is photolithographically patterned to define the silicon nitride 
membranes.  CF4-based reactive ion etching (RIE) first transfers the pattern to the 
backside SiN and SiO2 layers, then deep RIE based on the BoschTM process is performed 
to anisotropically etch through the wafer up to the front-side buried SiO2 layer, shown in 
Figure 2.2B.  This layer acts as a stop mask, and allows compensation for approximately 
10 percent etch non-uniformity commonly seen in the deep RIE processes [14]. The 
wafer is finally dipped in 49% HF for 2 minutes to remove the remaining oxide and 
release the silicon nitride membranes.  The wafers are then diced into 5 mm x 5 mm chips. 
 
2.4.2. Actuation Layer 
The actuation layer was also fabricated using micro-machining technology on 100 
mm SCS substrates. The process sequence is shown in Figure 2.3. The first step is to 
grow a 500 nm thermal SiO2 layer, which serves to electrically isolate the substrate.  A 
250 nm Ti layer followed by a 300 nm Au layer are sputtered next, shown in Figure 2.3A. 
The first photolithographic process is implemented to pattern Au electrical contacts, and 
is followed by Au and Ti wet etches to define the electrode layer shown in Figure 2.3B.  
The next steps are designed to encapsulate the resistors for protection against subsequent 
etch steps, and provide a robust adhesion layer for oxide deposition.  Sputtering of 300 
nm of Au and 20 nm of Ti is followed by the second photolithographic step.  Ti and Au 
layers are then wet-etched sequentially to define a capsule around the resistors, Figure 
2.3C.  The next step is to conformally deposit 2 μm of SiO2 to isolate the electrodes 
  26 
layers and prevent electrolysis between electrodes once the device is fully packaged and 
operating, Figure 2.3D.  The third photolithographic step is implemented to define vias 
for bonding pads in the electrodes, and open areas around the resistors.  A CF4-based RIE 
is used to etch SiO2 and the Ti adhesion layer to expose the bonding pads and the 
resistors.  The last photolithographic step masks the bonding pads.  This step is followed 
by an Au etch, finally exposing the Ti resistors.  The wafer is diced into 5 mm x 9 mm 
chips. 
 
2.4.3. Reservoir Layer 
The reservoir layer was defined using 100 mm, double-polished, 2.25 mm thick 
Pyrex 7740 wafers. These wafers were drilled using a 1.7 mm radius diamond bit to 
achieve a reservoir volume of 20 μL, and diced in 6 mm x 8 mm chips. 
 
2.4.4. Device Assembly and Loading 
All three layers were bonded together using a biocompatible UV-cured epoxy (1-
20542 cationic epoxy, Dymax Corporation, Torrington, CT). The layers can also be 
anodically bonded for permanent hermeticity.  The chip was loaded by breaking one of 
the nitride membranes and dispensing solutions with known drug concentration through 
the opening using a 100 μL syringe with a 32 Gauge needle (Hamilton Company, Reno, 
NV), mounted in an injection system consisting of a UMP-1 Ultra Micro Pump with 
Micro-1 controller and a Kite-R micromanipulator with a TB-1 tilting base (all from 
World Precision Instruments, Sarasota, FL).  This system allows precise control of the 
amount of solution injected into the device, and by extension, the amount of loaded drug.  
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The open membrane was subsequently sealed with UV-cured epoxy. Electrical wires and 
connectors were connected to the chip and wire-bonding was performed to connect the 
electrical wires to the chips. The final packaged device is shown in Figure 2.4. 
 
2.5. Experimental Methods 
Three sets of experiments were conducted to validate the device. The first 
experiment consisted of electrical characterization of the device in vitro by releasing a 
dye. Such a test was necessary to empirically determine the power consumption of the 
device and qualitatively determine the release rates. The second experiment consisted of 
quantitatively determining the release rates using radio-labeled vasopressin. The third 
experiment consisted of quantitatively determining the effects of the actuation 
mechanism (localized bubble nucleation) on drug degradation using high-pressure liquid 
chromatography (HPLC). 
 
 2.5.1. Electrical Characterization 
The devices were first tested in vitro by releasing methylene blue to determine the 
I-V curve characteristics while optically recording the release event. The devices were 
placed inside of a 10 mL beaker filled with deionized (DI) water. An increasing DC 
voltage was applied to the heating elements using a voltage source, and the current was 
measured. The device was optically inspected and recorded using a video camera 
connected to a stereoscope to register the conditions under which the dye was delivered. 
 
  28 
2.5.2. Quantification by Radioactive Release 
The amount of volume released by the device was determined using a solution of 
arginine vasopressin (Sigma-Aldrich, Inc., St. Louis, MO) and 3H-radiolabeled arginine 
vasopressin (American Radiolabeled Chemicals, Inc., St. Louis, MO).  Four devices were 
filled with 20 μL of radiolabeled solution following the procedure described above.  An 
additional three controls were injected directly into water to be measured and determine 
the loading in all devices.  The test devices were activated for 45 seconds with an applied 
voltage of 9 V in 2 mL of DI water.  The media was sampled immediately before and 
after each device activation.  Media aliquots were measured in a liquid scintillation 
counter (Packard Tri-Carb 2200CA, Perkin-Elmer Life Sciences, Waltham, MA) to 
determine the fraction of original loading that was released. 
 
2.5.3. Quantification by HPLC 
The effect of device actuation on the degradation of vasopressin was determined 
in three devices.  The devices were filled with 20 μL of a 25 mg/mL solution of arginine 
vasopressin and sealed.  Another 20 μL of solution was also directly injected into 5 mL 
of DI water as control, resulting in a concentration of 0.1 mg/mL.  Devices were activated 
as in the previous section in 5 mL of DI water and media samples were collected 
immediately after activation.  Samples were analyzed by reverse-phase HPLC (RP-
HPLC), using an Agilent 1200 Series with quaternary pump and diode array detector 
(Agilent, Inc., Santa Clara, CA).  A gradient method was used in a Brownlee Spheri-ODS 
column (25 cm x 4.6 mm, 5 μm, 100 Å, Alltech Associates, Deerfield, IL), with methanol 
and 0.1% trifluoroacetic acid (TFA) in water both obtained from Sigma-Aldrich, Inc. (St. 
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Louis, MO).  The gradient used was 2 % TFA/min, starting at 0%.  The flow rate was 1 
mL/min and the detection wavelength 220 nm.  The Chemstation software (Agilent, Inc., 
Santa Clara, CA) was used to measure the area under the observed retention peaks and 
calculate the area fraction of the vasopressin peak, yielding the fraction of intact 
vasopressin. 
 
2.6. Results 
2.6.1. Electrical Characterization 
Figure 2.5 shows the I-V curve of the heating elements. The red circle indicates 
that the device is intended for 9 V operation. Bubbles were observed for an applied DC 
voltage of 9 V and the measured current was approximately 650 mA. Figure 2.6 shows 
the methylene blue jetted into DI water during actuation. The electrical fuses on top of 
the membranes were also monitored during each activation and were observed to become 
open-circuited as the membranes burst, proving that it is possible to interrogate the device 
by means of impedance measurement to check whether the sealing membrane is opened 
by the device actuation. 
 
2.6.2. Radioactive Release Quantification 
Figure 2.7 shows the measured loading fraction released after each activation.  
The results indicate that 92.9 ± 0.7 % (n = 4) of the original loading was released by the 
devices. 
 
  30 
2.6.3. HPLC Quantification 
Vasopressin was found to have a retention time of 16.8 minutes.  The area 
fraction of the vasopressin peak for the devices was compared to that of the control, and 
it was found that 9.0 ± 0.7 % (n = 3) of the vasopressin released by the devices was 
degraded with respect to the original state of vasopressin injected into the devices, as 
shown in Figure 2.8. 
 
2.7. Discussion 
The device designed and fabricated in this work is an implantable device based on 
MEMS technology that provides a platform for applications requiring rapid drug delivery. 
The best candidates for this device are conditions of an urgent nature that would require a 
depot, but not necessarily intravenous access.  The actuation mechanism of the device is 
similar to inkjet printing, as it relies on film micro-boiling, but the volumes of liquid to be 
displaced are six orders of magnitude greater.  The resistors involved in the bubble 
nucleation process were designed to guarantee that the nucleation occurs in the film 
boiling regime.  The power density achieved is approximately 25 W/mm2 allowing an 
effective increase in the reservoir pressure, while guarantying that the bubble nucleation 
is in the film boiling regime. Electrical characterization showed that activation requires 
relatively high power for an implantable device, approximately 6 W for 45 seconds, but 
this device can be connected to commercially available ultra-high density capacitors, 
which can provide 240 J from a very small size component to power it.  Future 
generations of this device should try to reduce power consumption, notably by improving 
insulation of the device to reduce heat losses to the environment. 
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The degradation study by HPLC demonstrated that the heating involved in the 
actuation of the device does not significantly affect vasopressin in vitro, as 91 ± 0.7 % of 
the drug was still effective after release.  Quantification of device loading fraction 
released by radiolabeled vasopressin determined that 92.9 ± 0.7 % of the loaded solution 
was released in 45 seconds. It can therefore be inferred by simple multiplication of these 
two measurements that 84.5 ± 0.9 % of the drug originally loaded into the device is 
released in its active form. An overhead volume can thus be included when loading the 
device in order to deliver a consistent target dose. 
A potential issue related to the use of this device is the presence of silicon nitride 
fragments after activation.  One may worry that these fragments may damage 
surrounding tissue at the moment of membrane bursting or thereafter.  The mass of a 400 
x 400 x 0.2 μm piece of silicon nitride with a density of 3.4 g/cm3 is 0.11 ng.  It is 
unlikely that such a mass, upon bursting, would be able to significantly damage tissue 
around the device.  The fragments released after activation of the device are not expected 
to travel from the implantation site, and would eventually be surrounded by a fibrous 
capsule and isolated from the body.  Their presence is therefore not anticipated to be a 
problem.  In vivo testing of the device may bring answers to these questions, although the 
small size of the fragments may render this task difficult. 
Another solution to the problem is to use gold membranes instead of silicon 
nitride.  A gold membrane can be melted by passing a current pulse through it, as has 
been demonstrated in the past [7].  The limitation of this solution is the upper limit on 
size of gold membrane that ensured its mechanical integrity.  A dimension of 400 x 400 
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μm is not achievable in this author’s experience, and smaller openings may affect the 
performance of the device.  An optimization study may answer the question, however. 
 
2.8. Conclusions 
This device represents the first implantable drug delivery device specifically 
designed to rapidly provide medication.  It is a technology platform that can be leveraged 
for a large number of medical applications. It was shown to provide consistent drug 
delivery without any major degradation in the case of vasopressin. It is an ideal candidate 
for pathologies that require immediate and ambulatory treatment of high-risk individuals, 
and allows for rapid and effective treatment. Application of this technology platform can 
significantly improve survival rates in ambulatory settings. 
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2.9. Figures 
 
 
 
 
 
 
Figure 2.1: Cross section of the device showing the three layers: membrane layer (A), 
reservoir layer (B) and actuation layer (C). 
 
A
B 
C
Micro-resistor 
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Figure 2.2: Fabrication sequence for the membrane layer. (A) Electrodes on Au, 
deposited on Si3N4 (green) and SiO2 (red), followed by (B) through-wafer via etching by 
DRIE. 
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Figure 2.3: Fabrication process of actuation layer. (A) SiO2, Ti, Au deposition on SCS 
substrate. (B) Definition of electrodes and resistor. (C) Ti, Au encapsulation. (D) SiO2 
deposition. (E) Electrodes vias and exposure to Ti resistor. 
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Figure 2.4: Final packaged device showing the top chip with four silicon nitride 
membranes.  The device is wirebonded to detect opening of the far left membrane and to 
apply current to the microresistors.  Ruler graduations are in millimeters. 
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Figure 2.5: I-V curve of the device. The device was designed to be active at 9 V, 
indicated in red.  
 
 
 
Figure 2.6: Side view of device showing release of methylene blue into a solution upon 
activation. 
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Figure 2.7: Quantification of vasopressin release by radiolabeled species.  
 
 
 
 
Figure 2.8: HPLC analysis of released vasopressin from the device. 
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CHAPTER 3: IN VIVO PHARMACOKINETICS OF 
VASOPRESSIN 
 
3.1. Introduction 
The emergency delivery of vasopressin has one important requirement.  It must 
achieve systemic therapeutic levels as quickly as possible without direct intravenous 
delivery because a drug delivery device cannot currently deliver directly to the 
bloodstream.  An implanted device should therefore be placed in a location where the 
released drug is able to enter the circulatory system quickly.  Two candidate locations 
have been chosen for this study, the mesentery and a subcutaneous location. 
The mesentery is a highly vascularized region of the peritoneum, the lining of the 
abdominal cavity that envelops and protects the soft organs within it.  The mesentery 
attaches the gastrointestinal organs to the abdominal wall and supplies them with blood.  
A device placed in this region could release vasopressin and allow it to enter the 
bloodstream quickly.  Access to this location is invasive, however, as a surgery would 
most probably be needed to implant the device.  Future generations of the device may be 
able to shrink it to dimensions allowing it to be inserted with a catheter or other means 
without requiring major surgery.  Interest in this location may therefore still be warranted. 
The most non-invasive location to implant a device would be subcutaneous, in an 
arm or a leg, as the device could easily be implanted and retrieved later without major 
surgery.  A subcutaneous location is more peripheral than the peritoneum, however, and 
may not allow sufficient access to the circulatory system.  Desmopressin, a synthetic 
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vasopressin analogue with more specific anti-diuretic activity than vasopressin, has been 
used as a subcutaneous injection to control the frequent urination associated with diabetes 
insipidus (water diabetes) and chronic bedwetting [1].  It is also used subcutaneously for 
at-home self-treatment of some patients with bleeding disorders such as von Willebrand 
disease or mild hemophilia A [2, 3].  There is thus reason to believe that subcutaneous 
delivery of vasopressin may be able to achieve a systemic effect. 
The work presented hereinafter aims to investigate the pharmacokinetics of 
vasopressin injected into two candidate locations for implantation of an emergency drug 
delivery device.  Vasopressin was injected intraperitoneally into the mesentery and 
subcutaneously, and its effect on blood pressure in rabbits was evaluated.  Plasma levels 
of vasopressin were measured using radiolabeled vasopressin in order to corroborate with 
blood pressure and heart rate measurements.  They were also used to estimate 
bioavailability of these injection routes.  
 
3.2. Materials and Methods 
3.2.1. Animals 
This study was approved by MIT’s Committee on Animal Care and the Animal 
Care and Use Review Office from the Department of Defense Medical Research and 
Material Command.  Twenty-two male New Zealand White rabbits with weights between 
2.5 kg and 3.5 kg were obtained (Covance Research Products, PA). The animals were 
housed in compliance with MIT’s Committee on Animal Care husbandry guidelines, with 
unrestricted access to water and food. 
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3.2.2. Vasopressin 
Arginine vasopressin acetate powder (Sigma-Aldrich, Saint-Louis, MO) was 
reconstituted with sterile water to appropriate concentration for injection.  
3H-radiolabeled vasopressin (American Radiolabeled Chemicals, St. Louis, MO) was 
added to injection solutions for determination of plasma levels of vasopressin. 
 
3.2.3. Intraperitoneal Catheters 
Rabbits chosen to receive intraperitoneal injections were implanted with a sterile 
vascular access port (VAP) (Access Technologies, Skokie, IL), consisting of a silicone 
catheter and a polysulfone injection port with a silicone septum.  A laparotomy was 
performed to fix one end of the catheter to the connective tissue 1 cm from the root of the 
mesenteric arterial tree of the small intestine.  The other end was tunneled subcutaneously 
along the flank to the dorsum.  The injection port was fixed subcutaneously with sutures 
in a location caudal to the left shoulder blade through a dorsal skin incision and 
connected with the catheter.  Figure 3.1 illustrates the final configuration of the VAP.  
This setup allows solutions to be injected into the peritoneum reproducibly with a syringe.  
The clearance volume of the port and catheter is 400 μL.  All incisions were closed and 
rabbits were allowed to recover from the implantation surgery for a minimum of 7 days 
with appropriate analgesia and prophylaxis, before any injection experiments were 
performed. 
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3.2.4. Vasopressin Injections 
Rabbits were anesthetized with an initial dose of midazolam (2 mg/kg, 
intravenous) and were maintained under anesthesia by mask with 1-3% isoflurane in 
balance oxygen.  One ear was catheterized for intravenous access, while the central 
auricular arteries in both ears were catheterized for mean arterial pressure (MAP) 
monitoring and blood sampling, respectively.  The rabbits were monitored for up to 1 
hour after the start of data acquisition to let MAP stabilize to baseline before injecting 
vasopressin. 
Rabbits received 1 μg/kg vasopressin intravenously (IV001 group, n = 11), 
10 μg/kg intraperitoneally (IP010 group, n = 16), or 100 μg/kg subcutaneously (SQ100 
group, n = 5).  Sterile water was also injected intraperitoneally (IP000, n = 8) and 
subcutaneously (SQ000, n = 4) as placebo.  Rabbits were monitored for 1 hour following 
injection or activation then euthanized by sodium pentobarbital injection.  Rabbits 
allowed to wake up were left to recover for 7 to 14 days then received another injection.  
The total number of injections a rabbit received varied between 1 and 3. 
MAP was monitored and recorded continuously by direct blood pressure 
measurement from an arterial catheter in the central auricular artery, using a Blood 
Pressure AnalyzerTM 400 with DMSI software (Micro-Med, Louisville, KY).  Values 
were measured every 0.5 seconds and averaged over 10 seconds to yield a single data 
point. 
ΔMAP was defined as the difference between MAP and baseline MAP, which is 
the average MAP measured over 5 minutes before injection.  Plots of each injection were 
subsequently analyzed (Excel 2003, Microsoft, Inc., USA) to extract the maximum 
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ΔMAP (ΔMAPmax), the time needed to reach that maximum (tmax), and the time at which 
ΔMAP returned under baseline level for at least 1 minute thereafter (tdur).  Intraperitoneal 
injections often resulted in MAP not returning to baseline, but reaching a plateau higher 
than baseline.  The beginning of the plateau was considered as tdur in those cases. 
Unpaired, two-tailed, Student’s t-tests were conducted between groups to 
determine statistical significance with α = 0.05 when comparison was required. 
 
3.2.5. Bioavailability of Vasopressin 
Nine rabbits in this experiment were chosen to receive 3H-radiolabeled 
vasopressin solutions, three in each of the IV001, IP010 and SQ100 groups.  One blood 
sample was collected before injection as control and up to 7 samples after injection at 
chosen time points up to 1 hour.  Rabbits that received radiolabeled vasopressin were 
immediately euthanized at the end of the monitoring period with an intravenous injection 
of sodium pentobarbital. 
The drawn blood samples were collected into BD Vacutainer® tubes coated with 
sodium heparin (VWR, West Chester PA) and immediately refrigerated for further 
processing.  Samples collected within one day were centrifuged at the end of each day to 
collect plasma.  Plasma samples were then solubilized per manufacturer’s instructions 
using SOLVABLETM (PerkinElmer, Waltham, MA) and counted in a liquid scintillation 
counter (Packard Tri-Carb 2200CA, PerkinElmer, Waltham, MA) to determine plasma 
levels. 
The bioavailability F of a drug delivered by an experimental route or formulation 
is expressed by: 
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ref
∗
∗=  (Eq. 3.1) 
AUC is defined as the area under the plasma concentration versus time curve of 
the tested drug using the trapezoidal rule, up to the last collected data point [4].  The 
reference sample is generally an intravenous dose of the drug, as it allows all of the 
injected drug to be exposed to the body.  Each AUC is normalized by the given dose for 
comparison.  The average AUC up to one hour for each group was thus computed to 
obtain the absolute bioavailability after one hour for IP010 and SQ100. 
 
3.3. Results 
3.3.1. Vasopressin Injections 
Figure 3.2 shows average ΔMAP plots for each vasopressin group.  Placebo 
groups showed normal fluctuations from their baseline values and are not shown.  
Rabbits in the IV001 group experienced a sharp spike in MAP within 30 seconds after 
injection, which immediately subsided.  It was then followed by a rapid increase to the 
peak pressure and rapid decrease back to the baseline.  Rabbits in the IP010 and SQ100 
groups, in contrast, did not spike and experienced slower rates of increase to their peak 
MAP and subsequent decrease, as shown in Figures 3.2(b) and 3.2(c), respectively. 
Figure 3.3 shows a plot of ΔMAPmax vs. tmax as reported in Table 3.1 and tdur for all 
groups, respectively.  Rabbits in the IP010 and SQ100 groups experienced significantly 
higher ΔMAPmax (p < 0.05) than their respective placebo group.  These two groups were 
also not significantly different from each other for all parameters. 
 
  46 
3.3.2. Pharmacokinetics 
Figure 3.4 shows average plasma vasopressin levels measured by radiolabeled 
species in the 3 vasopressin groups.   IV001 showed rapid decay of the plasma 
vasopressin concentration from a nominal initial concentration of 22.2 ± 0.4 ng/mL to 2.9 
± 1.6 ng/mL after 8.7 minutes to a final concentration of 0.7 ± 0.3 ng/mL.  The decay did 
not appear to be exponential, but biphasic.  Data in the first 5 minutes suggested a t1/2 of 
2.2 minutes, and between 5 and 15 minutes, a t1/2 of 6.2 minutes.  The plasma 
concentration did not significantly decrease between 30 and 60 minutes. 
IP010 initially showed an induction period of 5 minutes or less before increasing 
to a peak concentration of 8.2 ± 3.7 ng/mL at 30 minutes, then decreased slightly over the 
next 30 minutes to a final value of 6.5 ± 1.0 ng/mL, which was not significantly different 
from its peak value.  Plasma levels for SQ100 increased linearly in the first 45 minutes at 
a rate of 0.77 ng/(mL min), after which they increased more slowly to reach a maximum 
concentration of 37.1 ± 9.2 ng/mL one hour after the injection.   
The measured bioavailability of IP010 was found to be 25.0 ± 13.3 % and for 
SQ100, 10.0 ± 6.3 %. 
 
3.4. Discussion 
This work is the first to the author’s knowledge to show intraperitoneal and 
subcutaneous injections of vasopressin at levels that achieved systemic vasoconstriction.  
The observed behavior of MAP in the different groups is consistent with the initially 
measured plasma level profiles. 
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The IV001 group shows an immediate spike in MAP as vasopressin is injected.  
The origin of the spike is unknown, and has never been reported to the best of the 
authors’ knowledge.  One possible explanation is that the response does not pertain to the 
whole circulatory system, but rather to a local response of the artery where the catheter is 
introduced, due to aggressive vasoconstriction triggered by a large bolus of vasopressin.  
Investigation of this phenomenon may yield useful medical data, but is beyond the scope 
of this research.  This instantaneous reaction, however, is likely one of the reasons why 
vasopressin is typically infused over time in traumatic hemorrhagic shock settings, rather 
than injected as a bolus.  A rapid spike in MAP may dislodge a clot that has formed on a 
severed blood vessel, and could cause further bleeding before surgical control may be 
achieved.  The rapid elimination of vasopressin from the circulatory system also explains 
the short duration of effect of an intravenous bolus.  King et al studied the half-life of an 
intravenous bolus of vasopressin (52 ng) in anesthetized rabbits and measured a t1/2 of 0.9 
minutes during the first 5 minutes and a t1/2 of 5.4 minutes for the remaining 20 minutes 
[5].  These values are lower than measured in this work, but the authors also mention 
differences with other studies based on the anesthetic agent used during experimentation, 
which could account for the observed difference. 
The IP010 and SQ100 groups show a more gradual change in MAP, consistent 
with the progressive increase in plasma vasopressin shown in the first 15 minutes after 
injection, at which point the MAP has peaked in both groups.  This observed behavior 
corroborates the concept of a bolus of vasopressin deposited intraperitoneally or 
subcutaneously and from which vasopressin gradually diffuses into the bloodstream to 
reach levels where systemic vasoconstriction can be measured.  This gradual increase in 
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vasopressin concentration is more similar to an infusion and would be preferred over an 
intravenous bolus. 
A discrepancy between measured levels and MAP behavior starts beyond 15 
minutes after injection.  Plasma levels suggest that MAP should remain high (IP010) or 
increase (SQ100), but it slowly decreases back to baseline values instead.  Dworkin et al 
observed the same phenomenon when they investigated vasopressin-induced 
vasoconstriction in the hepatic vascular bed in rats and found that the vasoconstriction 
was lost after 15 minutes of a 30-minute vasopressin infusion at ~1.5 μg/kg-min [6].  
Their investigation demonstrated that this loss of vasoconstriction was due to the local 
production of nitric oxide (NO), a vasodilator, which inhibited the action of vasopressin.  
NO is produced in the vascular endothelium by endothelial nitric oxide synthase (eNOS) 
in response to elevated intracellular levels of Ca2+ in the vascular smooth muscle, which 
cause vasoconstriction [7].  The produced NO allows the vascular smooth muscle to relax 
and brings vascular tone back to a normal condition.  Long-term inhibition of NO 
synthesis has further been shown to cause systemic hypertension [7-9].  eNOS is thus an 
important regulating component of vascular tone.  Vasopressin-induced vasoconstriction 
in healthy rabbits could therefore trigger the regulatory production of NO by eNOS to 
inhibit the action of vasopressin and maintain a normal vascular tone. 
Co-injection of vasopressin with one of the many known NO inhibitors, such as 
L-NAME (N(G)-nitro-L-arginine methyl ester), would show whether the loss of 
vasoconstriction observed in this work is due to regulatory NO synthesis.  Inhibition by 
NO may also possibly be avoided in a shock model, since the action of vasopressin would 
be compensatory rather than a stressor on the vascular system. 
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It is also noted that the doses used in this study were simply chosen to corroborate 
pharmacokinetic measurements with a measurable effect on blood pressure and heart rate.  
They are not necessarily in the therapeutic range, which would have to be determined by 
a dose-ranging study conducted in a shock model. 
The plasma concentration data obtained in this work was not sufficient for an 
estimation of total bioavailability.  Figure 3.4 shows that plasma levels for SQ100 were 
still rising after one hour, and were not declining significantly for IP010.  The real 
bioavailability for both of these injection routes is thus greater than the calculated values.  
The obtained values suggest that 25% of the intraperitoneal dose and 10% of the 
subcutaneous dose had entered the bloodstream after one hour.  These numbers agree 
with the initial assumption that the mesentery, being more vascularized than the 
subcutaneous site, would allow greater bioavailability.  They do not take into account the 
possible degradation of vasopressin in its injection site, however, because the assay 
method does not distinguish between whole and degraded vasopressin.  They are thus 
representative of the maximum bioavailability of vasopressin injected intraperitoneally or 
subcutaneously after one hour. 
 
3.5. Conclusions 
This work is the first to report on plasma profiles, effects and bioavailability 
measured after intraperitoneal and subcutaneous injections of vasopressin in healthy 
rabbits.  The obtained results demonstrate the potential for such injections to achieve 
prolonged vasoconstriction in shock models.  An important implication in the emergency 
treatment of hemorrhagic shock is the possibility of pre-treating a bleeding trauma patient 
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with a subcutaneous vasopressin injection before hospital arrival to sustain hemodynamic 
parameters and delay the onset of shock without the need for catheterization.  This 
method would be especially advantageous in chaotic conditions, where an intravenous 
catheterization cannot easily be performed. 
The candidate locations tested in this work for subsequent implantation of a drug 
delivery device both showed positive results and potential to release from either site.  The 
intraperitoneal site showed better bioavailability within the first hour, but the surgery 
needed to implant a device intraperitoneally is currently more invasive than for a 
subcutaneous implantation.  The logistics of implanting devices in all soldiers heading 
out to military operations theaters, for example, would require a location that is as simple 
to reach as possible.  The subcutaneous location was thus chosen for in vivo delivery of 
vasopressin from the rapid drug delivery device.  Further improvements to the device 
allowing it to be implanted without major surgery (as an injectable device, for example) 
may make the intraperitoneal location a more attractive site for implantation. 
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3.6. Figures 
 
 
 
 
to peritoneum
 
Figure 3.1: Schematic of vascular access port used in intraperitoneal injections.   
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Figure 3.2: Averaged ΔMAP profiles after vasopressin injection at t = 0 for groups (a)
IV001, (b) IP010 and (c) SQ100.  Solid lines are averages of all profiles in the group.
Dashed lines represent ± standard deviation. 
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Figure 3.3: Plots of (a) ΔMAPmax vs. tmax and (b) tdur.  Error bars represent standard 
deviation.  The legend is the same for both plots. 
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Figure 3.4: Levels of vasopressin as measured by radiolabeled species for the vasopressin 
groups.   
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3.7. Tables 
Table 3.1: Summary of ΔMAPmax, tmax and tdur for each test group.  Values are reported as 
mean ± standard deviation. 
Group n ΔMAPmax 
(mmHg) 
tmax 
(min) 
tdur 
(min) 
IV001 11 45.8 ± 12.1 3.7 ± 1.3 13.3 ± 5.3 
IP000 8 7.2 ± 6.0 13.1 ± 14.8 18.0 ± 18.3 
IP010 16 24.6 ± 8.5 13.3 ± 3.6 31.9 ± 15.2 
SQ000 4 5.5 ± 2.3 18.6 ± 17.1 20.2 ± 17.1 
SQ100 5 24.3 ± 11.5 12.0 ± 4.6 39.1 ± 23.0 
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CHAPTER 4: IN VIVO RAPID DELIVERY OF 
VASOPRESSIN FROM AN IMPLANTABLE DRUG 
DELIVERY MEMS DEVICE 
 
4.1. Introduction 
This chapter reports on the first in vivo subcutaneous release of vasopressin from 
the implantable rapid drug delivery device in a rabbit model, and has been submitted in 
part for publication to the Journal of Controlled Release.  Investigation of intraperitoneal 
and subcutaneous injections of vasopressin showed measurable effects from both delivery 
routes.  The subcutaneous location was chosen because of the less invasive procedure 
needed to implant the device.  Vasopressin was chosen as a model drug as it is widely 
used as vasoconstrictor in cardiac arrest [1, 2], and shows promise for use in hemorrhagic 
shock [3-7].  It is thus a potential candidate for release from the device in this time-
sensitive context.  Device releases were compared with intravenous and subcutaneous 
injections of vasopressin to assess bioavailability and compare pharmacokinetics with 
normal injections.  Placebo device releases were also performed to investigate possible 
effects from the device. 
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4.2. Materials and Methods 
4.2.1. Vasopressin 
Arginine vasopressin acetate powder (Sigma-Aldrich, Saint-Louis, MO) was 
reconstituted with sterile water to appropriate concentration for injection or device 
loading.  3H-radiolabeled vasopressin (American Radiolabeled Chemicals, St. Louis, 
MO) was added to injection solutions for determination of plasma levels of vasopressin. 
 
4.2.2. Devices 
Device fabrication and drug loading have been extensively described in Chapter 2.  
Three devices were filled with 20 μL of radiolabeled solution containing a vasopressin 
dose of 100 μg/kg and 4 devices were filled with 20 μL of sterile water. 
 
4.2.3. Animal Study 
This study was approved by MIT’s Committee on Animal Care and the Animal 
Care and Use Review Office from the Department of Defense Medical Research and 
Material Command.  Nineteen male New Zealand White rabbits with weights between 
2.5 kg and 3.5 kg were obtained (Covance Research Products, PA, USA). The animals 
were housed in compliance with MIT’s Committee on Animal Care husbandry guidelines, 
with unrestricted access to water and food. 
Rabbits were anesthetized with an initial dose of midazolam (2 mg/kg, IV) and 
were maintained under anesthesia by mask with 1-3% isoflurane in balance oxygen.  One 
ear was catheterized for intravenous access, while the central auricular arteries in both 
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ears were catheterized for mean arterial pressure (MAP) monitoring and blood sampling, 
respectively. 
Rabbits received 1 μg/kg vasopressin intravenously (IV001 group, n = 11), 100 
μg/kg subcutaneously (SQ100 group, n = 5), or were implanted with a device containing 
100 μg/kg vasopressin (DV100 group, n = 3) or sterile water (DV000 group, n = 4).  
Implanted devices were introduced through a skin incision on the left foreleg and placed 
subcutaneously over the tricep, with the drug exit side facing the muscle.  Biocompatible 
Teflon-sheathed electrical leads were used to connect the microheaters to the external 
power source through the incision.  Devices were activated by applying 9V to the 
microheaters for 10 seconds, followed by a 15 second pause and ten 5-second 
applications of 9V with 5-second intervals, in order to minimize heat exposure to the 
animal and drug degradation due to activations.  Rabbits were monitored for 1 hour 
following injection or activation then euthanized by sodium pentobarbital injection.  Four 
of the rabbits from the IV001 group were allowed to wake up from anesthesia, left to 
recover for 7 to 14 days then received another IV injection before being euthanized. 
MAP was monitored and recorded continuously by direct blood pressure 
measurement from an arterial catheter in the central auricular artery, using a Blood 
Pressure AnalyzerTM 400 with DMSI software (Micro-Med, Louisville, KY).  Values 
were measured every 0.5 seconds and averaged over 10 seconds to yield a single data 
point. 
ΔMAP was defined as the difference between MAP and baseline MAP, which is 
the average MAP measured over 5 minutes before injection.  ΔMAP plots for each 
injection were subsequently analyzed (Excel 2003, Microsoft, Inc., USA) to extract the 
  60 
maximum ΔMAP (ΔMAPmax), the time needed to reach that maximum (tmax), and the time 
at which ΔMAP returned under baseline level for at least 1 minute thereafter (tdur). 
Unpaired, two-tailed, Student’s t-tests were conducted between groups to 
determine statistical significance with α (significance level) = 0.05 when needed. 
 
4.2.4. Plasma Levels of Vasopressin 
Nine rabbits in this experiment were chosen to receive 3H-radiolabeled 
vasopressin solutions, three in each of the IV001, SQ100 and DV100 groups.  One blood 
sample was collected before injection as control and up to 7 samples after injection at 
chosen time points up to 1 hour.  Rabbits that received radiolabeled vasopressin were 
immediately euthanized at the end of the monitoring period with an intravenous injection 
of sodium pentobarbital. 
The drawn blood samples were collected into BD Vacutainer® tubes coated with 
sodium heparin (VWR, West Chester PA) and immediately refrigerated for further 
processing.  Samples collected within one day were centrifuged at the end of each day to 
collect plasma.  Plasma samples were then solubilized per the manufacturer’s instructions 
using SOLVABLETM (PerkinElmer, Waltham, MA) and counted in a liquid scintillation 
counter (Packard Tri-Carb 2200CA, PerkinElmer, Waltham, MA) to determine plasma 
levels. 
The bioavailability F of a drug delivered by an experimental route or formulation 
is expressed by: 
 
exp
exp
DoseAUC
DoseAUC
F
ref
ref
∗
∗=  (Eq. 3.1) 
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AUC is defined as the area under the plasma concentration versus time curve of 
the tested drug using the trapezoidal rule, up to the last collected data point [8].  The 
reference sample is generally an intravenous dose of the drug, as it allows for all of the 
injected drug to be exposed to the body.  Each AUC value is normalized by the given 
dose for comparison.  The average AUC up to one hour for each group was thus 
computed to obtain the absolute bioavailability after one hour for DV100 and SQ100. 
 
4.3. Results 
4.3.1. Vasopressin Delivery 
Figure 4.1 shows averaged ΔMAP profiles for all groups, while Table 4.1 
summarizes data analysis results.  Figure 4.1(a) shows the results for intravenous 
injections (IV001 group), demonstrating a sharp spike in MAP within 30 seconds after 
injection that immediately subsides.  It was then followed by a rapid increase to the peak 
pressure and rapid decrease back to the baseline.  Figure 4.1(b) shows the results for 
subcutaneous injections (SQ100 group), which, in contrast to subcutaneous injections, 
rose at a slower rate to a maximum peak then returned to baseline after almost 40 minutes.  
Figure 4.1(c) shows the results for the implanted microdevices (DV100 group), which 
exhibited a combination of both the intravenous and subcutaneous delivery modalities.  
The MAP reached a maximum peak significantly different from placebo in a time similar 
to an intravenous injection, but slowly returned to baseline after approximately 33 
minutes, similarly to a subcutaneous injection.  It also shows a slight dip in MAP within 
the first 2 minutes.  Figure 4.1(d) represents the results for the placebo device (DV000 
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group), which showed the same dip within the first 2 minutes, but no other notable 
feature. 
 
4.3.2. Pharmacokinetics 
Figure 4.2 shows measured plasma levels in the three groups that received 
vasopressin.  IV001 showed rapid decay of the plasma vasopressin concentration from an 
estimated initial concentration of 22.2 ± 0.4 ng/mL to a final concentration of 0.7 ± 0.3 
ng/mL.  A bi-phasic exponential decay was measured with a t1/2 of 2.2 minutes in the first 
5 minutes, and a t1/2 of 6.2 minutes between 5 and 15 minutes.  The plasma concentration 
did not significantly decrease between 30 and 60 minutes.  Plasma levels for SQ100 
increased linearly in the first 45 minutes at a rate of 0.77 ng/(mL min), after which they 
increased more slowly to reach a maximum concentration of 37.1 ± 9.2 ng/mL one hour 
after the injection.  Plasma levels in DV100 animals initially rose to 5.1 ± 1.3 ng/mL after 
3.6 minutes, but increased at a slower rate of 0.35 ng/(mL min) thereafter to reach a final 
concentration of 24.4 ± 2.9 ng/mL after one hour. 
The bioavailability of DV100 was calculated to be greater than 6.2 ± 2.8 % and 
for SQ100, greater than 10.0 ± 6.3 %, for the same reasons outlined in the previous 
chapter. 
 
4.4. Discussion 
This work has shown that a MEMS drug delivery device implanted 
subcutaneously was able to deliver a dose of vasopressin capable of showing a 
measurable effect on blood pressure in healthy rabbits.  Peak effect was achieved within 
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5 minutes and lasted approximately 30 minutes.  Results suggest that vasopressin quickly 
entered the circulatory system causing an increase in MAP as early as 2 minutes after the 
start of activation.  The similar behavior observed following a subcutaneous injection and 
the measured pharmacokinetic profile both support that this MAP increase was due to the 
release of vasopressin.  The release of vasopressin from a device results in a rapid onset 
effect with relatively long duration, potentially making the device superior to both 
intravenous and subcutaneous injections in terms of therapeutic efficacy.  Testing of the 
device in a shock model will provide the definitive answer. 
The bioavailability of vasopressin released from the device was found to be lower 
than that from a subcutaneous injection of the same dose.  This reduced bioavailability 
may be due to incomplete release from the device or the difference in volume and 
concentration of vasopressin administered via each delivery route, which may vary the 
entrance rate of vasopressin.  It is to be noted, however, that the standard deviation of the 
device results is much smaller than that of the subcutaneous injections, be it in the ΔMAP 
profile or plasma levels.  A drug delivered from the device may be able to reach more 
consistent pharmacokinetics than simple injections.  Increased sample size for device 
release of vasopressin is needed to confirm this. 
The power applied during activation of the device was cycled because of concern 
that the thermal energy released by the device may degrade vasopressin.  The cycling of 
power did not significantly degrade the vasopressin, but the released thermal energy may 
have slightly affected the animals.  A small dip in MAP was observed during activation 
of the loaded and placebo devices.  Reduction of the thermal energy released to the 
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environment by better insulation is an objective for improvement of future generations of 
the device. 
The extended duration of effect achieved by subcutaneous injection and device 
release of vasopressin correlates with initial plasma levels, but at times beyond the peak 
pressure, this effect is progressively lost, despite the continually increasing plasma levels.  
The observed discrepancy between blood pressure and plasma level is similar to that 
observed by Dworkin et al, who reported a loss of vasoconstriction after 15 minutes of a 
30-minute infusion of vasopressin directly to the hepatic arterial bed in rats [9].  Their 
work demonstrated that this loss of vasoconstriction was tied to the triggered production 
of nitric oxide (NO), which caused vasodilation.  It is conceivable that the injection of 
vasopressin in a healthy animal is seen as a stressor, thus triggering a regulatory 
mechanism through NO synthesis to bring the blood pressure back to normal levels.  A 
device release of vasopressin in a hemorrhagic shock model may therefore show a more 
extended effect than seen in this work, because the vasoconstriction would be 
compensatory, rather than a stressor. 
An alternative explanation for the loss of vasoconstriction is the degradation of 
vasopressin over time, either in the blood or before entering the bloodstream, although it 
has been shown not to degrade in rat serum in vitro for up to 8 hours [10].  Injection or 
release of vasopressin in the presence of a NO inhibitor such as L-NAME (N(G)-nitro-L-
arginine methyl ester) should tip the scale toward one of these hypotheses, depending on 
whether it prolongs vasoconstriction in healthy animals. 
Another point to address if this device is to be used in a hemorrhagic shock model 
is that in such models the peripheral circulation is already reduced due to reduced blood 
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volume and vasoconstriction of the peripheral arterioles.  Total peripheral vascular 
resistance is increased in this situation and may hamper the pharmacokinetics of 
vasopressin.  The increasing plasma levels of vasopressin seen in this work despite 
vasoconstriction suggest that this may not be a problem, although the reduced blood 
volume may play a role in shock.  This issue is only valid in a hemorrhagic shock model.  
Other conditions where peripheral circulation is not affected would not encounter such 
issues. 
This work did not address the issues of long-term implantation, where the 
formation of a fibrous capsule around the device may prevent diffusion of vasopressin.  
Work by Prescott et al, however, has shown that this capsule does not affect the 
pharmacokinetics of leuprolide, another polypeptide with similar molecular weight to 
vasopressin [11].  Vasopressin could be similarly unaffected, but investigation of the 
effect of the fibrous capsule on the diffusion of vasopressin will be required to confirm 
the viability of the device for long-term use.  Long-term implantation would also affect 
the stability of vasopressin in solution.  A dual-chamber concept for the device is being 
investigated for that purpose, where the drug would be kept in a lyophilized form in one 
chamber.  The drug would be rapidly reconstituted and released with media kept in a 
separate chamber upon activation. 
 
4.5. Conclusions 
This work is the first to demonstrate the in vivo delivery of vasopressin from a 
MEMS drug delivery device producing a measurable effect on blood pressure in rabbits.  
The results obtained in this work warrant further investigation of the device in a 
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hemorrhagic shock model.  Further research is required to address issues associated with 
long-term implantation.  Its application could extend beyond vasopressin to address acute 
conditions treatable with other drugs, such as atropine or epinephrine. 
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4.6. Figures 
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Figure 4.1: Average ΔMAP profile for groups (a) IV001, (b) SQ100.  Dashed lines 
represent ± standard deviation. 
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Figure 4.1: Average ΔMAP profile for groups (c) DV100 and (d) DV000.  Dashed lines 
represent ± standard deviation. 
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Figure 4.2: Vasopressin plasma levels measured by liquid scintillation counting 
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4.7. Tables 
Table 4.1: Summary of ΔMAPmax, tmax and tdur for each test group.  Values are reported as 
mean ± s.d.  p-values are results of student-t tests compared with DV100. 
Group ΔMAPmax 
(mmHg) 
p tmax 
(min) 
p tdur 
(min) 
p 
IV001 45.8 ± 12.1 < 0.05 3.7 ± 1.3 0.61 13.3 ± 5.3 < 0.05 
SQ100 24.3 ± 11.5 0.26 12.0 ± 4.6 < 0.05 39.1 ± 23.0 0.65 
DV100 17.2 ± 4.2 --- 4.0 ± 0.9 --- 33.9 ± 6.0 --- 
DV000 4.7 ± 0.7 < 0.05 15.7 ± 22.6 --- 18.0 ± 21.6 --- 
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CHAPTER 5: TELEMETRIC ACTIVATION AND RAPID 
RECONSTITUTION 
 
5.1. Introduction 
Two of the requirements delineated in Chapter 1 for an implantable emergency 
drug delivery device are long-term stability of the drug and the ability for telemetric 
activation, since the time until the device is needed is unknown, but activation must be 
available immediately at the push of a button if no sensors are integrated with the device 
for a closed-loop system.  This chapter presents proof-of-concept experiments conducted 
for the requirements of the device developed in this work. 
 
5.2. Rapid Reconstitution Device 
5.2.1. Introduction 
Drugs in aqueous solutions are seldom stable for long periods of time due to 
hydrolization.  Vasopressin retains at least 95% of its intact form for only 3 days in water 
at 37°C, for example.  Many drugs are stored in lyophilized form, due to the solid phase 
being more stable, which also allows them to withstand higher temperatures.  This feature 
is desirable for an implanted drug delivery device with unknown time to activation.  The 
requirement for rapid drug delivery, however, does not allow the drug to remain in solid 
form when the device is activated, since diffusion by itself would not allow rapid delivery. 
One solution to the problem would be to physically expel the lyophilized drug 
from the device, although this solution would require a moving component, which is not 
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always reliable.  Another concept, presented in this work, is a dual-reservoir design for 
the drug delivery device.  The original device as presented in this work is first filled with 
reconstitution media.  An additional Pyrex reservoir containing the lyophilized drug is 
appended to the device and is capped by a second membrane chip.  The reservoirs are 
thus hermetically separated by a silicon nitride membrane chip.  Activation of the device 
breaks the intermediate membrane and expels the liquid into the drug, reconstituting it 
then further forcing the solution out of the device. 
 
5.2.2. Experimental Method 
A proof-of-concept experiment was conducted on one device.  The first reservoir 
was loaded with 20 μL of water and sealed as previously described.  The second reservoir 
was then loaded with 4 mg of atropine sulfate (Sigma-Aldrich, Inc., St. Louis, MO), a 
drug used as an anti-nerve gas agent.  The reservoir was covered with a waterproof 
adhesive tape to allow filming of the reconstitution event inside the second reservoir, and 
the tape was slit with a razor blade to allow fluids to escape.  Figure 5.1 shows the device 
before activation.  The device was placed under a stereoscope fitted with a digital camera 
to record the event.  A voltage of 9 V was applied to the microresistors of the device for 
25 seconds then removed. 
 
5.2.3. Results 
Figure 5.2 shows frames of the reconstitution event captured by the camera.  The 
device is activated at t = 0 s (Figure 5.2(a)).  The intermediate membrane breaks at 
t = 8.233 s, represented in Figure 5.2(b) and evidenced in the video by a sudden shift in 
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the atropine.  The difference is not obvious with a still image.  Darkening of the powder 
shown in Figure 5.2(c) at t = 12.067 s signals the diffusion of water up to the upper layers 
of the atropine reservoir.  Fluid starts exiting the slit in the tape immediately afterwards, 
shown in Figure 5.2(d).  The amount of fluid exiting the device increases steadily from 
there onwards, as shown in Figures 5.2(e) and 5.2(f).  The activation is terminated at t = 
25 s.   
 
5.2.4. Discussion 
This experiment indicates that rapid reconstitution and release from an 
implantable device may be possible, although the amount of drug expelled from the 
device was not quantified.  One approach to increase reconstitution and release yield is 
using a smaller powder chamber.  This configuration will decrease the amount of space 
between powder particles and will allow the liquid to come in contact with all of the 
powder more easily.  Another approach is to force the liquid to move through all of the 
contained powder before being able to exit the device.  This approach would allow 
maximum interaction between the liquid and powder for reconstitution and expulsion of 
the drug. 
 
5.3. Telemetric Activation 
5.3.1. Introduction 
Implantable biomedical devices are developed for the purpose of surpassing 
current diagnostic or treatment limitations.  The drug delivery device developed in this 
work, for example, aims to allow rapid drug delivery in situations when it may not be 
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possible otherwise.  Interfacing of this device with in vivo sensors developed by other 
researchers could lead to a closed-loop system able to detect and automatically handle an 
emergency.  There may be cases where in vivo sensors may not detect the emergence of 
symptoms or do not exist for the symptoms to be detected, however, and a wireless, 
manual control would be required to activate the drug delivery device.   
This section presents a proof-of-concept for wireless activation of the device with 
power supplied by 9V batteries in a military scenario of remote casualty search and 
treatment.  This experiment was conducted in collaboration with Prof. Bordetsky from 
the Naval Postgraduate School, Monterey, CA at the Camp Roberts military camp in 
California. 
 
5.3.2. Experimental Method 
Three devices were loaded with 20 μL of a solution of 1 mg/mL methylene blue 
(Sigma-Aldrich, Inc., St. Louis, MO) as previously described.  Three controls of 20 μL 
were also injected into square plastic cuvettes with 3 mL of deionized (DI) water.  
Devices were placed inside similar cuvettes containing 3 mL DI water, with Teflon-
sheathed electrical leads extending through the cuvette lids.  Each device was connected 
to a control system linked to a Blackberry phone to receive the activation signal, as 
shown in Figure 5.3.  The control system included a signal transducer to transform an 
auditory signal of 1 kHz relayed by the Blackberry to an “ON” state for a switch that 
closed the circuit to which the device was connected.  Power for the control system and 
device was provided by four 9 V batteries connected in parallel. 
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Each device was activated for 45 seconds in a separate cuvette, after which the 
device was removed and absorption at 668 nm was measured from each cuvette using a 
UV-vis absorption spectrometer.  Each control was also measured with serial dilutions to 
obtain a calibration curve, which was used to quantify the amount of solution released 
from each device.  The calibration curve was linear with concentration (not shown). 
 
5.3.3. Results 
Measurements obtained from the three devices revealed that 84.6 ± 2.1 % of the 
loading was released when activated wirelessly and powered by 9V batteries. 
 
5.3.4. Discussion 
This work has provided proof-of-concept for the wireless activation of the drug 
delivery device developed in this work.  Quantification of the release with methylene 
blue revealed that devices connected to 9V batteries released a smaller fraction of their 
loading than devices connected to a stable power supply (84.6% vs. 92.9%, respectively).  
This result is expected, since the batteries are not expected to sustain the same voltage as 
a power supply while being drained continuously for 45 seconds.  Starting and ending 
voltages were measured for 5 other devices previously activated in the same fashion (not 
shown).  The starting voltage was measured to be 8.24 ± 0.11 V and the average voltage 
drop after 45 seconds of current application was 0.24 ± 0.04 V.  The smaller voltage 
applied to the devices thus explains the reduced release volume because of reduced 
power output.  No quantitative comparisons could be made, however, because current 
was not recorded as a function of time. 
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The results obtained in this study, while providing proof of concept, highlight one 
of the major deficiencies of the current device.  The current and power consumption of 
the device are very high for a device to be implanted with a limited power supply.  Four 
standard 9V batteries were needed to provide enough current to the device for operation.  
Ultra-high density capacitors may be able to deliver enough current to the device, but it is 
expected that these capacitors would lack the capacity to sustain activation for 45 seconds.  
The greatest improvements needed for future generations of this device are in reducing 
heat losses to the surroundings.  This will improve device performance on all fronts, from 
duration of activation to total current and power consumed, and will thus allow the device 
to function within more realistic constraints.  Other modes of drug expulsion which do 
not produce heat might also be considered, but they either rely on moving parts which 
have lower reliability (e.g., micro-pumps) or on electrochemical reactions which have 
shown lesser reproducibility. 
 
5.4. Conclusions 
The results obtained from the experiments presented in this chapter have provided 
complementary proof-of-concept to the rapid drug delivery device developed in this 
research, towards a realistic system.  They have opened a new avenue of research in the 
use of this device for rapidly reconstituting drugs, and highlight the need for improving 
device performance through reduction of heat losses.  Alternate systems may be 
considered, but may result in lower reliability or reproducibility. 
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5.5. Figures 
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Figure 5.1: Picture of assembled rapid reconstitution device.   
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(a) t = 0.000 sec 
 
(b) t = 8.233 sec 
 
(c) t = 12.067 sec 
 
(d) t = 12.567 sec 
 
(e) t = 15.000 sec 
 
(f) t = 25.000 sec 
Figure 5.2: Image capture of rapid reconstitution experiment.  Times indicated are with 
respect to the start of activation.  The arrow indicates the slit that allows fluids to escape. 
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Figure 5.3: (a) Picture of wireless activation control system.  The system was placed on a 
mannequin to simulate a wounded soldier in the military search-and-rescue scenario 
including the activation of the devices.  (b) Picture of device during wireless activation. 
 
Batteries 
Blackberry 
Receiver 
Control 
System Device 
(a) 
(b) 
  81 
CHAPTER 6: SUMMARY AND FUTURE OPPORTUNITIES 
6.1. Summary 
The first implementation of a rapid drug delivery device for emergency therapy 
has been demonstrated in this work, culminating with the release of vasopressin in rabbits.  
The device was fabricated using MEMS technology and presents a modular architecture 
allowing customization of each part.  Its operation is based on the nucleation of vapor 
bubbles inside the drug reservoir by heated micro-resistors to expel the drug solution.  In 
vitro characterization of the device showed reliable and reproducible vasopressin release 
with limited degradation for an applied potential of 9 V for 45 seconds. 
Intraperitoneal and subcutaneous implantation locations were investigated.  The 
subcutaneous location, despite needing approximately 100 times the intravenous dose to 
show a measurable effect, was chosen because of the less invasive nature of implantation. 
The device was implanted subcutaneously in rabbits with a pre-determined dose 
and activated.  Effects of the released drug were monitored by continuous blood pressure 
measurements.  Plasma levels of vasopressin as a function of time were also measured by 
liquid scintillation counting of plasma samples to detect radiolabeled vasopressin mixed 
with the release solution.  The bioavailability of vasopressin delivered by the device one 
hour after activation was calculated from plasma level measurements to be 6.2%.  This 
experiment demonstrated the potential of the developed device to deliver drugs in a 
timely manner in emergency therapies. 
Additional proof-of-concept experiments were conducted with the device.  A 
dual-chamber design with the device as a base was used to demonstrate the possibility for 
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rapid reconstitution and delivery of a lyophilized drug.  A battery-powered, wireless 
control system was also implemented to achieve remote activation of the device. 
 
6.2. Future Opportunities 
6.2.1. Device Development 
The first generation of the device managed to establish the possibility for rapid 
and reliable in vivo drug delivery from an implantable device, but its power production 
and current requirement were too high to be easily implemented for real-life use.  
Another concern came from the heat dissipated to the surroundings of the device during 
activation that may damage biological tissues.  A final concern was that the duration of 
activation resulted in large energy consumption, which current capacitors or batteries 
could not supply while sustaining the current needed by the micro-resistors during 
activation. 
All of these problems can be addressed by redesigning the device to reduce heat 
loss.  Reduction of heat loss will lead to lower power requirements, less potential tissue 
damage and shorter activations.  The heat produced by the micro-resistors will 
predominantly produce vapor bubbles rather than be conducted away by the substrate.  
Alternative heatless means of expelling the liquid from the device could also be explored, 
although reliability and reproducibility of these means will have to be determined and 
compared to the current mechanism. 
An interesting avenue for future research is the dual-chamber concept for rapid 
reconstitution that was summarily demonstrated.  Successful implementation of this 
system could address long-term stability of drugs in the device.  The remaining issue 
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regarding the long-term implantation device is the effect of the fibrous capsule, which 
would inevitably form around the implanted device, on the pharmacokinetics of 
vasopressin or any other drug released by the device.  This issue may adversely affect the 
performance of the device by delaying drug entry into the bloodstream, and if so, would 
have to be addressed for continued success of the device in enabling emergency therapy. 
 
6.2.2. Short-Term Applications 
Current protocols and requirements, if vasopressin were to be used in 
hemorrhagic shock, would require the establishment and maintenance of intravenous 
access for an infusion, which can be difficult in highly dynamic and chaotic conditions, 
such as those found on battlefields.  Figure 6.1 shows an example of intravenous infusion 
implemented in an evacuation vehicle.  An unexpected result obtained in this work was 
the finding that a subcutaneous injection of vasopressin was able to achieve sustained 
vasopressin levels, much like an intravenous infusion.  This result opens new possibilities 
for the rapid delivery of vasopressin in emergency situations.   
The first and simplest possibility is the direct subcutaneous injection of 
vasopressin by a medic on the battlefield following assessment of the hemorrhage.  A 
device to inject drug solutions subcutaneously could be used for that purpose, or a simple 
syringe would suffice.  The optimal location remains to be determined, but this solution 
could be implemented the fastest.  Investigation of intramuscular injections of 
vasopressin may render the procedure even simpler if positive results are obtained.  The 
use of subcutaneous vasopressin to address hemorrhagic shock is the object of a 
technology disclosure submitted to MIT’s Technology Licensing Office. 
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The possibility of using subcutaneous injections also opens the doors for a more 
technological solution which does not require implantation.  Figure 6.2 shows a 
conceptual render of such a solution, in the form of an armband to be worn by soldiers.  
The externalization of the device removes space and power limitations on the device, 
allowing all necessary components to be located on the armband with current technology.  
One or several spring-loaded syringes could be placed on it, along with control 
electronics, batteries and wireless antenna for remote activation by a medic.  A rapid 
reconstitution device similar to the one demonstrated in this work in the syringe may also 
be implemented to allow for longer shelf life.  The device would have to be ruggedized to 
withstand shocks, but could more easily be implemented than an implanted device, and 
would be more likely to be accepted by soldiers.   
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6.3. Figures 
 
 
 
 
 
 
 
Figure 6.1: Wounded soldier in an evacuation vehicle with intravenous infusion bag.  
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Figure 6.2: Conceptual render of an armband designed to inject vasopressin or other 
drugs subcutaneously in case of emergency.  The armband would contain a number of 
spring-loaded syringes which can be activated to inject their load upon wireless triggering 
by a medic. 
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